“Significant Step Forward” for Actinogen’s Alzheimer’s treatment

By Maggie Lynch

- Last updated on GMT

© wildpixel / Getty Images
© wildpixel / Getty Images

Related tags: Alzheimer's disease, Actinogen, Xanamem, Phase 2a, Clinical trial

Clinical data findings from Actinogen’s Phase 2a study measuring the effects of Xanamem in patients with biomarker-positive Alzheimer’s Disease validated company’s ongoing program.

Actinogen’s trial found that patients with elevated blood pTau, above the median value, showed a clinically significant Xanamem effect on the CDR-SB endpoint. CDR-SB will be a primary endpoint in the company’s upcoming Phase 2b trial.

Paul Rolan, chief medical officer at Actinogen stated the results of the trial “are a significant step forward in the development of Xanamem as a new treatment for Alzheimer’s Disease (AD) with a novel, amyloid-independent mechanism of action.”

The findings of the Phase 2a trial validate a clear path for regulatory approval as the company moves forward with clinical research in the AD space.

The Phase 2a trial in biomarker-positive patients used available blood biomarker levels in 72 patients from the company’s prior study, XanADu. The XanADu study had 185 patients with mild AD.

“We are very pleased to see such positive clinical data for patients with biomarker-positive, mild AD. The results extend findings of therapeutic effects on cognition in two prior trials of cognitively normal, older volunteers to patients with early AD,”​ said Rogan.

A CDR-SB effect of .6 to 8 points represents a 60 to 80 percent reduction in disease progression over 12 weeks compared to placebo. The Phase 2a trial data also showed that 56 percent of patients in the Xanamem group were stable or in improved condition compared to the placebo group.

Additionally, data showed that elevated blood pTau had a clinically significant effect in Neurologic Test Battery (NTB) and Mini Mental State Exam (MMSE).

Rogan explained that the data from the Phase 2a trial validates the dose range planned for Actinogen’s upcoming trials in AD and depression.

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

Related suppliers

Follow us

Products

View more

Webinars